期刊
VIRUSES-BASEL
卷 14, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/v14112429
关键词
feline infectious peritonitis; FIPV; coronavirus; antiviral; pharmacokinetics; combined anti-coronaviral therapy
类别
资金
- EveryCat Health Foundation [W21-007]
- University of California, Davis Peter C. Kennedy Endowed Fellowship (2021-2022)
- University of California Center for Companion Animal Health [2020-89-FM]
- NIH/NIAID [R21AI15924601]
- National Institutes of Health [NIH 5K01OD026526]
Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks effective vaccines or treatments. This study aimed to determine and compare the antiviral efficacies of several drugs in vitro and evaluate their pharmacokinetic properties. The results showed that certain drug combinations exhibited synergy against FIPV, the causative agent of FIP.
Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks licensed and affordable vaccines or antiviral therapeutics. The disease has a spectrum of clinical presentations including an effusive (wet) form and non-effusive (dry) form, both of which may be complicated by neurologic or ocular involvement. The feline coronavirus (FCoV) biotype, termed feline infectious peritonitis virus (FIPV), is the etiologic agent of FIP. The objective of this study was to determine and compare the in vitro antiviral efficacies of the viral protease inhibitors GC376 and nirmatrelvir and the nucleoside analogs remdesivir (RDV), GS-441524, molnupiravir (MPV; EIDD-2801), and beta-D-N-4-hydroxycytidine (NHC; EIDD-1931). These antiviral agents were functionally evaluated using an optimized in vitro bioassay system. Antivirals were assessed as monotherapies against FIPV serotypes I and II and as combined anticoronaviral therapies (CACT) against FIPV serotype II, which provided evidence for synergy for selected combinations. We also determined the pharmacokinetic properties of MPV, GS-441524, and RDV after oral administration to cats in vivo as well as after intravenous administration of RDV. We established that orally administered MPV at 10 mg/kg, GS-441524 and RDV at 25 mg/kg, and intravenously administered RDV at 7 mg/kg achieves plasma levels greater than the established corresponding EC50 values, which are sustained over 24 h for GS-441514 and RDV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据